Voyageur Pharmaceuticals (TSE:VM) has released an update.
Voyageur Pharmaceuticals Ltd. has developed five new barium contrast agents for medical imaging, which promise to set new industry standards and offer competitive advantages. These products are now entering the final phase of clinical testing and will be positioned as new drugs in the U.S. market, utilizing a streamlined FDA approval process. The company aims to enhance the value for stakeholders by launching these products in Canadian and international markets after the upcoming patient trials.
For further insights into TSE:VM stock, check out TipRanks’ Stock Analysis page.
